Brief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
20/10/2026 07:14
BRIEF-Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP Oct 20 (Reuters) - Mabion SA MABP.WA:
PARTNER ODDIFACT SAYS FDA CONSULTATIONS ALLOW MABIONCD20 TO BE USED AS FIRST-LINE THERAPY FOR ITP
CLINICAL TRIAL OBSERVATION PERIOD FOR MABIONCD20 CAN BE SHORTENED TO 24 WEEKS FROM 52 WEEKS
SHORTENED OBSERVATION PERIOD EXPECTED TO ACCELERATE MABIONCD20 DEVELOPMENT, MAY REDUCE COSTS AND PARTICIPANT BURDEN
FINAL PROTOCOL AND ASSESSMENTS TO BE SUBMITTED TO FDA IN DECEMBER 2026
Source text: ID:nEM9rGTmqa
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects